Netherlands to Limit Use of Janssen Vaccines Due to Effectiveness and Possible Side effects

Young adults in Netherlands who have not been vaccinated against COVID-19 will not receive the Janssen vaccine, which is a single-shot product that does not require a booster.

According to Health Minister Hugo de Jonge, these young group of people will be offered approved mRNA vaccines from Pfizer/BioNTech or Moderna. 

The Dutch Health Council noted that the mRNA vaccines have a higher efficacy rate and have less adverse effects than the vaccines from AstraZeneca and Johnson & Johnson subsidiary Janssen.

These vaccines have been observed to have serious side effects involving blood clots along with a low platelet count. 

The research center Lareb hasn’t found a single report of these side effects after the Janssen vaccine was administered in the Netherlands, though it has occurred internationally. 

The Dutch Health Council has found that after the vaccination with AstraZeneca, those in the younger age groups had been diagnosed with thrombosis with a low platelet count at the same rate as the Janssen vaccine.

The last group who will be vaccinated with the Janssen Vaccine are those who are born in 1976. 

Those who cannot easily be contacted for the second dose, such as homeless people, will receive the Janssen vaccine as well.

The Dutch Health Council advises that  the AstraZeneca vaccine should only be used for people over 60 years of age due to the scientific data that has been found about it recently. 

Those who also refuse to be vaccinated with the AstraZeneca vaccine can be inoculated with one of the mrNA vaccines instead.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.